Data from this study will support a submission to expand the use of atogepant to include preventive treatment of chronic migraine in the United States and additional submissions globally
Selvax's goal is to develop safe, effective and immunological-based treatments for a range of hard-to-treat solid tumours
The breakthrough approval expands the existing indication of Jardiance to include adults with heart failure with preserved ejection fraction (HFpEF), an underserved patient population that previously had no approved therapies in Europe
Collaboration aims to capture patient-to-patient variability to determine the best treatment for every cancer
This ninth update of WHO’s guideline on therapeutics includes a recommendation that casirivimab-imdevimab not be used for patients infected with the Omicron variant
Viralex is an immunomodulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body's defence response to viral infections
USFDA's industry recommendations and cancer Moonshot aim to improve lives of patients and their families
In a European work-sharing procedure (WSP), Glucophage was approved as the first oral anti-diabetic medication to be used safely from conception to birth
Evrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated to date
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
Subscribe To Our Newsletter & Stay Updated
